IMMX immixbio.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
Immix Biopharma, Inc. (IMMX) focuses on the rapid expansion of clinical trials to combat tumors and autoimmune pathologies, leveraging alliances with oncology centers and the acquisition of innovative startups. This price action, featuring an EV/EBITDA metric of 0.00, complements the analysis of the business developing NXC-201 CAR-T therapy, which demonstrates success in treating myeloma and possesses potential for outpatient use.
פילוחי נתונים אנליטיים מרוכזים עבור immixbio.com (IMMX)
The diversified immunotherapy pipeline of Immix Biopharma, Inc. (IMMX) allows the company to mitigate development risks, which is reflected in the fluctuations of the EV/EBITDA multiple over time. This ratio correlates the total enterprise value (market capitalization plus net debt) with operating profit before depreciation and amortization, enabling investors to determine the fair value of the asset regardless of debt load or tax regime to identify optimal entry points.
